Here is a look at the coronavirus

1. RACE TO COVID19 VACCINE AND TESTING
PAUL YOUNG CPA CGA
JUNE 23, 2020

2. PAUL YOUNG CPA CGA – BIO
September 9,
2014
• CPA, CGA
• Financial Solutions
• SME – Risk Management
• SME – Emerging Technology
• SME – Business Process Change
• SME – Close, Consolidate and
Reporting
• SME – Public Policy
• SME – Financial Solutions
• SME – Supply Chain Management
Contact – Paul.Young@ca.ibm.com

3. INTRODUCTION
This presentation takes a look at what is happening with the COVID19 vaccine development.

4. AGENDA
 Pharma and Vaccines development
 Key Companies
 CANSINO BIOLOGICS INC.(6185)
 Symvivio Corporation
 Novovax
 CureVac
 Generex
 Vaxart
 Medicago
 Takis
 Altimmune
 Testing
 Testing Kits
 Global Market / Testing
 Effective Treatments
 Antibodies
 Summary

5. MAJOR PLAYERS / VACCINES DEVELOPMENT

6. FINANCIAL PERFORMANCE KEY COMPANIES

7. CANSINO
BIOLOGICS
INC.(6185)
 100% of the revenue is in China -
https://www.marketscreener.com/CANSINO-BIOLOGICS-INC-
59318312/company/
 The chair is McGill graduate. https://www.marketscreener.com/business-
leaders/Xue-Feng-Yu-0DD2L9-E/biography/ Trudeau attended McGill and
McGill has high Chinese enrolment -
https://www.mcgill.ca/international/channels/news/mcgill-news-china-
tops-international-enrolment-mcgill-first-time-291377
 J&J and Casino have similar vaccine -
https://www.reuters.com/article/health-coronavirus-vaccine/special-
report-countries-companies-risk-billions-in-race-for-coronavirus-
vaccine-idUSL2N2CF0JG. China is ahead of the curve. China weakness has
always been with real facts.
 https://www.fiercepharma.com/vaccines/china-s-cansino-pushes-
coronavirus-vaccine-into-clinical-testing-as-moderna-doses-1st “The
green light was doled out very quickly. It was only Tuesday when CanSino
said it had filed the pre-IND review application for the vaccine to
authorities and was in the process of a rolling submission of technical
documents. CanSino’s candidate, dubbed Ad5-nCoV, uses its adenovirus-
based viral vector vaccine platform. In 2017, the same technology helped
the company earn a Chinese nod for its Ebola vaccine, which was the first
Ebola shot approved anywhere based on the strain behind the deadly
epidemic in West Africa in 2014.
 Trial of COVID19 drug back by the Military -
https://twitter.com/dockaurg/status/1262018934569664515
 Last 10K filed was 2017 - https://fintel.io/filings/us/casbf
 Only 2018 showed revenue

8. SYMVIVIO
CORPORATION
 Early VC company working with Canadian government -
https://pitchbook.com/profiles/company/185411-98#funding (Key investor -
National Research Council Canada
 https://www.dnb.com/business-directory/company-
profiles.symvivo_corporation.31108ce6e17eb52f4e64c097dc36f2f7.html
“Symvivo Corporation is in Burnaby, BC, Canada and is part of the
Biotechnology Research Services Industry. Symvivo Corporation has 3 total
employees across all of its locations and generates $580,698 in sales (USD).”
 Small venture capital and pre-trials - https://www.trialsitenews.com/ubc-
dalhousie-university-commence-study-of-the-bactrl-spike-vaccine-targeting-
covid-19/ “According to one profile, the venture has raised $2 million from a
local early state venture investor and $100K from a National Research Council.
Founder Graves started the company, along with Mark Fox—a friend from
undergrad—as he realized “he sucked” at research but desired to leverage his
scientific degree in meaningful ways. Graves and Fox sought to develop a
platform that could accelerate drug development by focusing on the
discovery—developing patents for aspects of the drug delivery process that
could be licensed to drug makers”

9. NOVOVAX
 A small group of scientists, execs, and VCs are $277 million richer as their companies
race to create a coronavirus vaccine. Here are 7 who have raked in huge sums. -
https://markets.businessinsider.com/news/stocks/coronavirus-drugmakers-moderna-
gilead-novavax-stock-price-profit-millions-shareholders-2020-2-1028949761
 Stock sales due to trials -
https://www.bizjournals.com/washington/news/2020/05/20/novavax-prepares-stock-
sale-as-covid-19-vaccine.html
 https://finance.yahoo.com/news/novavax-nvax-stock-come-too-224659672.html
“Vaccine specialist Novavax (NVAX) stepped up to the plate, and hit the ball out of
the park yet again. Investors had already enjoyed some pretty hefty gains in 2020
before more positive developments sent the stock into the stratosphere. Last week,
news that Novavax had received a $384 million grant from the Coalition for Epidemic
Preparedness Innovations (CEPI) to support the development of its COVID-19 vaccine
candidate, NVX-CoV2373, resulted in a 133% addition to the share price”
 Coalition Preparedness https://cepi.net/about/whoweare/ - CEPI has secured
financial investment from the Governments of Australia, Belgium, Canada,
Denmark, Ethiopia, Finland, Germany, Japan, the Kingdom of Saudi Arabia, the
Netherlands, Norway, the UK and Switzerland, as well as the Bill & Melinda
Gates Foundation, and Wellcome. The European Commission provides
substantial financial contributions to support relevant projects through its
mechanisms. CEPI has also received donations from the private sector and
individuals through the UN Foundation’s COVID-19 Solidarity Response Fund to
support our COVID-19 vaccine development efforts.

10. CUREVAC
 As the race to develop a coronavirus vaccine intensifies, one player—
German drugmaker CureVac—is backed by particularly deep pockets.
CureVac, which is in the headlines amid rumors that the U.S.
government offered funding to lure its research exclusively to
America, counts one of Germany’s richest entrepreneurs, Mexican
shopping mall tycoons and the Bill and Melinda Gates Foundation
among its investors.
https://www.forbes.com/sites/martaorosz/2020/03/16/these-are-the-
billionaire-investors-behind-german-drugmakers-developing-a-
coronavirus-vaccine/#78c83f841fb8
 Regulators / Germany https://www.ft.com/content/7409dbae-6b4f-
4be0-ba75-46ed52e951ae
 In the race to find a medical breakthrough to the pandemic, the
startup, CureVac, said earlier this month that its proprietary
technology has found suitable candidates that could lead to a
treatment, and that it aims to start clinical trials in early summer.
CureVac has received funding from the Bill & Melinda Gates
Foundation. - https://fortune.com/2020/03/16/coronavirus-cure-
trump-businesses-biotech/

11. GENEREX
 Manufacturing of peptide -
https://www.globenewswire.com/news-
release/2020/05/04/2026744/0/en/Generex-Biotechnology-
Initiates-Peptide-Manufacturing-for-Ii-Key-SARS-CoV-2-Peptide-
Vaccine-Against-the-COVID-19-Pandemic.html
 Stock/Generex- https://www.fool.com/investing/2020/05/17/is-
buying-a-basket-loaded-with-every-coronavirus-v.aspx “BIO, the
biggest trade group representing the biotechnology industry,
currently lists 28 companies that are actively involved in
developing COVID-19 vaccines. Here are the 21 of those
drugmakers that are publicly traded:”

12. VAXART
 SOUTH SAN FRANCISCO, Calif., May 20, 2020 (GLOBE NEWSWIRE) --
Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-
stage biotechnology company developing oral recombinant vaccines
that are administered by tablet rather than by injection, today
announced that it has selected its lead COVID-19 vaccine candidate
and has contracted with KindredBio to manufacture bulk vaccine
under cGMP to complement the manufacturing capacity of partner
Emergent BioSolutions https://www.globenewswire.com/news-
release/2020/05/20/2036357/0/en/Vaxart-Announces-Selection-of-
its-Oral-COVID-19-Vaccine-Lead-Candidate.html
 Funding issues - https://seekingalpha.com/article/4334623-vaxarts-
coronavirus-stock-bump-is-unlikely-to-continue-exit-now-be-long
 Cash on hand - https://www.fool.com/investing/2020/04/28/why-
vaxart-stock-slumped-today.aspx
 Partnerships - https://observer.com/2020/05/covid-19-vaccine-
moderna-results-new-progress/

13. MEDICAGO
 Quebec Funding -
https://www.canadianmanufacturing.com/research-and-
development/government-of-quebec-providing-7m-to-
medicagos-covid-19-vaccine-development-249412/
 Animal Trials - https://www.sttinfo.fi/tiedote/medicago-
announces-positive-results-in-animal-trials-for-its-vaccine-
candidate-against-covid-
19?publisherId=58763726&releaseId=69881188
 Collaborative project of more than $1.2 million using artificial
intelligence to optimize the production of vaccines, announced
by CQDM and Medicago R&D - https://www.newswire.ca/news-
releases/collaborative-project-of-more-than-1-2-million-using-
artificial-intelligence-to-optimize-the-production-of-vaccines-
announced-by-cqdm-and-medicago-r-amp-d-859733879.html

14. TAKIS
 “TAKIS SRL is located in ROMA, ROMA, Italy and is part of the
Scientific Research & Development Services Industry. TAKIS SRL
has 15 employees at this location and generates $1.78 million in
sales (USD). There are 4 companies in the TAKIS SRL corporate
family. https://www.dnb.com/business-directory/company-
profiles.takis_srl.1084976c4f88cf6ddd4089044968c511.html
 Startup -
https://www.forbes.com/sites/giacomotognini/2020/04/21/inside
-the-tiny-italian-biotech-startup-racing-to-develop-a-
coronavirus-vaccine/#b686e172c106
 Funding - https://finance.yahoo.com/news/applied-dna-takis-
biotech-announce-070000273.html

15. UPDATE –
VACCINES /
DEVELOPMENT
Source - “”
https://www.healthline.com/healt
h-news/heres-exactly-where-
were-at-with-vaccines-and-
treatments-for-covid-19

16. VACCINES DEVELOPMENT
 GSK - https://indianexpress.com/article/coronavirus/coronavirus-covid-19-vaccine-glaxosmithkline-oxford-
astrazeneca-moderna-clover-status-check-6469474/
 Vaccine Tracker - https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
 Gavi organization funding from sources like Bill Gates and world governments - https://www.biopharma-
reporter.com/Article/2020/06/17/Gavi-receives-billions-in-funding
 Gates and Inovio - https://www.newsbreak.com/missouri/kansas-city/news/0OfXdfSR/a-potential-coronavirus-
vaccine-funded-by-bill-gates-is-set-to-begin-testing-in-people-with-the-first-patient-expected-to-get-it-
today

17. ALTIMUNE
 “Shares of Altimmune (ALT) - Get Report soared Thursday after
the clinical-stage biopharmaceutical company announced the
next step in development of its coronavirus vaccine AdCovid. “In
collaboration with the University of Alabama at Birmingham, we
have commenced preclinical testing of candidates for our Covid-
19 vaccine, AdCovid,” the company said in a statement.
https://www.thestreet.com/investing/altimmune-coronavirus-
vaccine-preclinical-trial
 Former Pfizer board director appointed to Altimmune -
https://www.reuters.com/companies/ALT.OQ

18. TESTING
 COVID19 – Testing “It uses a simple assay containing plasmonic gold
nanoparticles to detect a color change when the virus is present. The
test does not require the use of any advanced laboratory techniques,
such as those commonly used to amplify DNA, for analysis. The authors
published their work last week in the American Chemical Society’s
nanotechnology journal ACS Nano. "Based on our preliminary results,
we believe this promising new test may detect RNA material from the
virus as early as the first day of infection. Additional studies are needed,
however, to confirm whether this is indeed the case,” said study leader
Dipanjan Pan, PhD, professor of diagnostic radiology and nuclear
medicine and pediatrics at UMSOM.”
https://www.umaryland.edu/news/archived-news/may-2020/covid-19-
results-in-10-minutes-umb-studies-rapid-test.php or
https://www.nextbigfuture.com/2020/05/ten-minute-covid-19-
detection-test-using-
nanoparticles.html?utm_source=feedburner&utm_medium=feed&utm_
campaign=Feed%3A+blogspot%2Fadvancednano+%28nextbigfuture%
29

19. TESTING KITS
Source - https://www.medtechdive.com/news/coronavirus-tests-home-collection-quest-diagnostics-
letsgetchecked/578837/
The cost is $129 per kit!

20. GLOBAL MARKET / TESTING
Source - https://www.globenewswire.com/news-release/2020/06/01/2041269/0/en/Global-COVID-19-diagnostic-testing-market-to-amass-USD-44481-8-million-in-2020.html
• Additional costs to already strapped healthcare system
• Private insurance companies and their coverage in terms of their testing. This could mean a rise in premiums
• Consumers could be out of pocket about $129 per test.

21. TREATMENT OPTIONS

22. ANTIBODIES
 “Much remains to be learnt about the immunological responses to SARS-CoV-2. Nevertheless, it is becoming clear that antibodies taken from the
blood serum of people who have recovered from COVID-19 can be used for treatment by being transfused into other people who have the
disease”Source - https://www.nature.com/articles/d41586-020-01816-5
 Disappearance of antibodies 2-3 months - https://www.medscape.com/viewarticle/932671
 “Those who did not have a bad case of COVID-19 lose antibodies faster. Forty percent of asymptomatic individuals became seronegative and
12.9% of the symptomatic group became negative for IgG in the early convalescent phase. In addition, asymptomatic individuals exhibited lower
levels of 18 pro- and anti-inflammatory cytokines. These data suggest that asymptomatic individuals had a weaker immune response to SARS-
CoV-2 infection.mThe research, published in Nature Medicine on June 18, highlights the risks of using COVID-19 ‘immunity passports’ and
supports the prolonged use of public health interventions such as social distancing and isolating high-risk groups This seems to indicate that our
better bet is t-cell-related therapies and vaccines and hygiene and social distancing.
 Avoid getting together with larger groups
 Stay 6-10 ten feet apart if at all possible
 clean your hands every hour
 Source - https://www.nextbigfuture.com/2020/06/coronavirus-antibody-immunity-fades-by-70-within-2-3-
months.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+blogspot%2Fadvancednano+%28nextbigfuture%29

23. GENE RESEARCH
 Genome sequencing - https://globalnews.ca/news/7072424/alberta-researchers-genome-sequence-covid-19/
 AI and Genome sequencing - http://www.genomequebec.com/486-en/news-covid-19-unprecedented-
research-combining-genomics-and-artificial-intelligenceicial-intelligence/
 Blood type and genome - https://directorsblog.nih.gov/2020/06/18/genes-blood-type-tied-to-covid-19-risk-
of-severe-disease/

24. TRAINING AND DEVELOPMENT
 If you like to learn more
about trade and/or other
subjects as part of your
professional learning and
development then feel free
to review my material on
https://www.udemy.com/
(search Paul Young CPA
CGA)
 These subjects address how
to fixed issues with housing
and/or systemic issues
related to economy
including government
policies

25. SUMMARY
 There are many companies involved with research and development of COVID19
vaccine -
https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=677
 Bill and Melinda Gates Foundation are playing a key role with funding and
manufacturing - https://www.geekwire.com/2020/gates-foundation-commits-50m-
covid-19-vaccine-initiative-total-funding-now-tops-300m/ (Funding is now over
$300M (USD)
 There are allot of startups involved. Various Canadian governments have been
funding VC companies related to biotech research
 There appears to be lack of progress reports on the state of affairs when it comes to
government money going to vaccinations R&D -
https://cmajnews.com/2020/05/20/coronavirus-1095847/
 There is allot of speculator investments going on with biotech companies as part of
reaping the rewards when vaccines go to market.
 Major pharma continues to work with government, institution, labs, Tech, etc.
https://www.bioworld.com/articles/435263-astrazeneca-moving-at-warp-speed-with-
12b-in-barda-funding-for-covid-19-vaccine
 Economy could see periods of slow growth for years -
https://www.slideshare.net/paulyoungcga/transforming-the-economy-postcovid19-
canada-and-the-world or https://www.investmentexecutive.com/news/research-and-
markets/covid-19-to-reshape-economy-society-moodys/